Top
Pediatric Fanconi Anemia Subtype A - Healing Genes
746
post-template-default,single,single-post,postid-746,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Pediatric Fanconi Anemia Subtype A

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A

A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the FANCA Gene in Pediatric Subjects With Fanconi Anemia Subtype A


Phase 1

DESCRIPTION:

Doctors at Stanford University Institute for Stem Cell Biology and Regenerative Medicine Lucille Packard Children’s Hospital (CA) are recruiting pediatric participants with Fanconi Anemia Subtype A for a study on how well a gene-modified immunotherapy correct the FANCA gene mutation that causes Fanconi anemia. The treatment consists of a self-transplant of the patient’s own stem cells, after they have been drawn and gene-modified in a lab setting to impart the correct gene, then multiplied in number. The goal is to have the stem cells populate the bone marrow and compensate for their genetic mutation.

The study will require leukapheresis (drawing of the stem cells) and, several days after they have been gene-modified, infusion of the  stem cells. Follow up will continue for 3 years and consist of lab and physical assessments.


PATIENT MUST:

  • Be 1 to 12 years of age
  • Be diagnosed with Fanconi anemia, as diagnosed by chromosomal fragility assay per the study’s lab criteria
  • Patient must meet not have an available and medically eligible human leukocyte antigen (HLA)-identical sibling donor.

THE STUDY INVOLVES:

  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. White blood cells will be drawn and over several weeks, the patient will receive no treatment while the cells are gene-modified in a lab.
  3. The investigatory treatment is infused once.
  4. Follow up will continue for at least 3 years.

LOCATIONS AND CONTACTS:

The study site is at Stanford University Institute for Stem Cell Biology and Regenerative Medicine of Lucille Packard Children’s Hospital, Stanford, California. Map.

 

Contact: Sandeep Soni, MD  |  1-650-725-9250  |  [email protected]

Contact: Agnieszka Czechowicz, MD, PhD  |  1-650-497-2218  |  [email protected]

 

SPONSOR INFORMATION:

Rocket Pharmaceuticals Inc.

 

Or go online:

https://clinicaltrials.gov/ct2/show/NCT03814408

 

 

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader